Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
(delayed)Notice of Release of Transcript of Interim Financial Results Briefing for the Fiscal Year Ending August 31, 2026
Announcement of International Nonproprietary Name (INN) for CTX-177
For 2nd quarter FY8 2026 Financial Results Presentation
Non-consolidated Financial Results for the Six Months Ended February 28, 2026 [Japanese GAAP]
Chordia Therapeutics, First Half Net Income Loss Narrows, Dec-Feb Net Income Loss Narrows
Notice of the First Patient Dosed in the Initial Expansion Cohort of rogocekib
Notice of Publication of a Joint Research Paper with Kyoto University on CDK12 Inhibitor CTX-439
Notice Regarding the Initiation of Expansion Cohorts for rogocekib
(Delayed)Notice Regarding Execution of a Termination Agreement for the CTX-177(ONO-7018) License Agreement
Notice Concerning Change of Major Shereholder
Chordia Therapeutics Publishes Phase 1 Results of CLK Inhibitor Rogocekib for R/R AML/HR-MDS in Blood Advances (Follow-up announcement)
Chordia Therapeutics, Sep-Nov (1Q) Ordinary Profit Loss Narrows
Non-consolidated Financial Results for the Three Months Ended November 30, 2025
By FISCO Corporation Notice of Distribution of Our Corporate Research Report
(Delayed)Notice of Investigator Meeting for rogocekib Development
Notice Regarding the Recording of Non-Operating Income (Grant income)
Corporate Governance Report
(Delayed)Chordia announces the Release of a Transcript of the Earnings Briefing for the Fiscal Year Ended August 2025
Announcement on the Reduction of Capital Reserve and Appropriation of Surplus
Publication of Research on the Discovery of CLK Inhibitor Rogocekib (Follow-up announcement)